Browsing by author "Banerjee, Susana"
Now showing items 1-20 of 32
-
An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancer.
Berner, AM; Hughes, DJ; Tharmalingam, H; Baker, T; Heyworth, B; et al. (2020-11)Introduction Over one million people in the UK identify as LGBTQ+ (lesbian, gay, bisexual, transgender, queer or questioning). Research has shown that this population experience differing cancer risk factors compared with ... -
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ... -
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.
Castelo-Branco, L; Awada, A; Pentheroudakis, G; Perez-Gracia, JL; Mateo, J; et al. (ELSEVIER, 2021-08-16) -
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; et al. (2016-12)Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ... -
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George, A; Kaye, S; Banerjee, S (2017-05)The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA ... -
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.
Winfield, JM; Wakefield, JC; Dolling, D; Hall, M; Freeman, S; et al. (2019-11)Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary and recurrent disease. ... -
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam, F; Makker, V; Oaknin, A; Oh, D-Y; Banerjee, S; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2024-01-01)PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. ... -
First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussion.
Banerjee, S; Gonzalez-Martin, A; Harter, P; Lorusso, D; Moore, KN; et al. (2020-11)Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines ... -
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan, RD; Clamp, AR; Barnes, BM; Timms, K; Schlecht, H; et al. (BMJ PUBLISHING GROUP, 2023-08-07)OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the ... -
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
Chazan, G; Franchini, F; Alexander, M; Banerjee, S; Mileshkin, L; et al. (2020-12)Objectives: To report clinician-perceived changes to cancer service delivery in response to COVID-19. Design: Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical ... -
The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.
Lim, KHJ; Murali, K; Thorne, E; Punie, K; Kamposioras, K; et al. (2021-12-17)<h4>Background</h4>COVID-19 has had a significant impact on the well-being and job performance of oncology professionals globally. The European Society for Medical Oncology (ESMO) Resilience Task Force collaboration set ... -
Improving outcomes for older women with gynaecological malignancies.
Dumas, L; Ring, A; Butler, J; Kalsi, T; Harari, D; et al. (2016-11)The incidence of most gynaecological malignancies rises significantly with increasing age. With an ageing population, the proportion of women over the age of 65 with cancer is expected to rise substantially over the next ... -
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham, RN; Slomovitz, BM; Andrews, N; Banerjee, S; Brown, J; et al. (BMJ PUBLISHING GROUP, 2023-09-04)Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many ... -
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Oaknin, A; Oza, AM; Lorusso, D; Aghajanian, C; Dean, A; et al.Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum-based chemotherapy and baseline disease. Methods Patients were ... -
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Grisham, RN; Vergote, I; Banerjee, S; Drill, E; Kalbacher, E; et al. (AMER ASSOC CANCER RESEARCH, 2023-10-13)PURPOSE: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). PATIENTS AND METHODS: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. ... -
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew, Y; Kim, J-W; Penson, RT; O'Malley, DM; Parkinson, C; et al. (American Association for Cancer Research (AACR), 2024-01-05)PURPOSE: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib ... -
Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
DiSilvestro, P; Banerjee, S; Colombo, N; Scambia, G; Kim, B-G; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-01-01) -
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro, P; Banerjee, S; Colombo, N; Scambia, G; Kim, B-G; et al. (American Society of Clinical Oncology (ASCO), 2022-09-09)PURPOSE: In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with ... -
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza, A; Kaye, S; Van Tornout, J; Sessa, C; Gore, M; et al. (2018-05)BACKGROUND:Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients ... -
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Moore, KN; Oza, AM; Colombo, N; Oaknin, A; Scambia, G; et al.Background Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The randomized, ...